The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BRKR | -35.31% | -6.8% | -1.4% | +76% |
| S&P | +14.5% | +93.32% | +14.09% | +358% |
Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment designs, manufactures, and distributes enabling life science tools based on magnetic resonance technology. The BSI CALID segment includes the design and distribution of life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.
Investors weren't overjoyed to hear about a mandatory convertible stock issue.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $797.40M | -0.4% |
| Gross Profit | $362.30M | -7.0% |
| Gross Margin | 45.44% | -3.2% |
| Market Cap | $6.24B | -35.3% |
| Market Cap / Employee | $0.55M | 0.0% |
| Employees | 11.4K | 17.4% |
| Net Income | $4.20M | -44.7% |
| EBITDA | $84.00M | -29.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $92.00M | -45.8% |
| Accounts Receivable | $635.00M | 4.6% |
| Inventory | 1.2K | 3.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.38B | 6.1% |
| Short Term Debt | $55.70M | 111.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 1.30% | -5.9% |
| Return On Invested Capital | 10.45% | -1.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$148.80M | -533.2% |
| Operating Free Cash Flow | -$127.50M | -11690.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 33.25 | 77.19 | 79.49 | 78.64 | 196.50% |
| Price to Book | 5.79 | 4.92 | 3.55 | 3.44 | -47.57% |
| Price to Sales | 3.24 | 2.65 | 1.84 | 1.82 | -40.03% |
| Price to Tangible Book Value | -15.08 | -12.80 | -9.91 | -10.11 | -123.35% |
| Price to Free Cash Flow TTM | 82.78 | 84.22 | 44.03 | 332.45 | 387.20% |
| Enterprise Value to EBITDA | 90.93 | 75.75 | 69.96 | 103.05 | 6.17% |
| Free Cash Flow Yield | 1.2% | 1.2% | 2.3% | 0.3% | -79.47% |
| Return on Equity | 20.2% | 7.2% | 4.9% | 4.4% | -81.00% |
| Total Debt | $2.42B | $2.25B | $2.11B | $2.44B | 7.30% |
BRKR earnings call for the period ending September 30, 2021.
BRKR earnings call for the period ending March 31, 2020.
BRKR earnings call for the period ending December 31, 2019.
BRKR earnings call for the period ending September 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
